CHLA Clinical Research Studies
Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.
By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.
In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.
Please contact the study staff listed in your search results for more information.
Back to the full listing
|Study Details - ID: CHLA-17-00209|
Relapsed or Refractory Acute Myelogenous Leukemia (AML)
TACL Decitabine + Vorinostat Epigenetic study in AML
|Full Title of Study:|
T2016-003: Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML
|Phase/Type of Study:|
Phase I drug treatment
|Purpose of Research:|
The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.
Age 1 to 25 with leukemia (AML) that has returned after an initial response to treatment
Treatment on this study consists of two courses of therapy which will last approximately 2 months.
Dr. Deepa Bhojwani
|Coordinator Contact Name:|
Ellynore Florendo, CCRC or Meg Fender, CRC -III
|Clinical Trials .Gov Identifier:NCT03263936|